Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00965861 | SCRI Tissue Testing Registry | terminated | — | 20 | SCRI Development Innovations, LLCOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT01923935 | Busulfan and Melphalan Conditioning in Multiple Myeloma | unknown | Phase 2 | 105 | Chonnam National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00934154 |
| Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma |
| completed |
| Phase 3 |
| 122 |
| Cigdem Sahinbas YILMAZINDUSTRY |
| 1 |
| Aug 15, 2013 |
| clinicaltrials |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | terminated | N/A | 4 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT00315757 | Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 105 | Human Genome Sciences Inc.INDUSTRY | 4 | Aug 8, 2013 | clinicaltrials |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies | terminated | — | 15 | University of California, San FranciscoOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01487031 | Music Therapy on Nausea and Pain for Autologous Stem Cell | completed | N/A | 108 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00480363 | QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression(QUIREDEX) | completed | Phase 3 | 120 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00723359 | Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT01060202 | Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib | completed | — | 60 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Jul 17, 2013 | clinicaltrials |
| NCT01892852 | Acupuncture for Chemotherapy-induced Peripheral Neuropathy | unknown | N/A | 36 | Pusan National University HospitalOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT01402687 | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) | completed | — | 181 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01440556 | Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma(MM2011) | completed | — | 196 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | terminated | Phase 1 | 9 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | terminated | Phase 2 | 1 | University of VirginiaOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01868828 | A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | unknown | Phase 4 | 50 | Peking University People's HospitalOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01695590 | Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Prolexys PharmaceuticalsINDUSTRY | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT01859234 | 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma | unknown | N/A | 20 | University Medical Center GroningenOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT01292486 | Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure | completed | N/A | 32 | Terumo BCTINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01268774 | Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. | completed | — | 529 | LEO PharmaINDUSTRY | 0 | Apr 18, 2013 | clinicaltrials |
| NCT00440635 | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma | completed | — | 641 | Janssen-Cilag International NVINDUSTRY | 0 | Apr 16, 2013 | clinicaltrials |
| NCT01829412 | Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma(MMY-MRI-08) | completed | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Apr 11, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | terminated | Phase 2 | 5 | SymBio PharmaceuticalsINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01030302 | A Retreatment Study With Bortezomib for Multiple Myeloma | completed | — | 56 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Mar 8, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2013source: clinicaltrials